Relapsed Diffuse Large B-Cell Lymphoma: Clinical Trials

2 trials for Relapsed Diffuse Large B-Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Terminated 2

Follow Relapsed Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Relapsed Diffuse Large B-Cell Lymphoma trials Research Report on Relapsed Diffuse Large B-Cell Lymphoma

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
MT-3724, Gemcitabine, Oxaliplatin - Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma
Phase 2TerminatedMolecular Templates, Inc.82018-08-202022-08-16
Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
Atezolizumab, Rituximab, Gemcitabine 1000 mg - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Phase 2TerminatedUniversity Hospital Southampton NHS Foundation Trust532018-05-092022-08-22

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (2)  ·  Recurrence (1)

Broader conditions

Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoma (2)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Disease Attributes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Gemcitabine (2)  ·  Oxaliplatin (2)  ·  Rituximab (1)  ·  atezolizumab (1)

Sponsors

Molecular Templates, Inc. (1)  ·  University Hospital Southampton NHS Foundation Trust (1)

Countries

United Kingdom (1)  ·  United States (1)

Top investigators

Andy Davies (1)

NIH funding

2016 (1)